The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
News|Videos|January 9, 2025
Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer
Sponsored Content: Benjamin H. Lowentritt, MD, FACS reviews Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer
Advertisement
This educational activity is brought to you by Janssen Biotech, Inc., and is not certified for continuing medical education. The consultant has been paid an honorarium by Janssen Biotech, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with the U.S. Food and Drug Administration (FDA) requirements applicable to Janssen.
Advertisement
Related to this article
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Five Huntsman Cancer Institute at the University of Utah colleagues earned endowed chair appointments, including new appointments.
The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
The OncFive: Top Oncology Articles for the Week of 7/19
5